Most Read Articles
Stephen Padilla, 03 Feb 2020
Treatment with semaglutide leads to clinically significant decreases in haemoglobin A1C (HbA1c) and body weight in patients with type 2 diabetes (T2D) across the SUSTAIN 1–7 trials, regardless of race and ethnicity, results of a posthoc analysis have shown.
2 days ago
Use of metformin is effective in preventing hyperglycaemia in nondiabetic cancer patients exposed to high-dose prednisone-based chemotherapy, results of a randomized study have shown.
Pearl Toh, 06 Feb 2020
The type I interferon receptor subunit 1 mAb* anifrolumab significantly improves response in patients with systemic lupus erythematosus (SLE) in the second phase III randomized trial of the drug, TULIP-2** — in contrast to the first trial.
27 May 2020
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.

Product Highlight - Alunbrig

30 Apr 2020
Alunbrig is indicated for the treatment of patients with ALK+ metastatic NSCLC who have progressed on or are intolerant to crizotinib1:

• Unprecedented Survival2*:
- 16.7 months median PFSa (95% CI: 11.6-21.4, n=110)
- 34.1 months median OS (95% CI: 27.7 - NR, n=110)
• Robust Response2*:
- 56% confirmed ORRa (95% CI: 47-66, n=110)
• Durable CNS Efficacy2*:
- 18.4 months median intracranial PFSa,b (95% CI: 12.6-23.9, n =74)
- 67% confirmed intracranial ORRa,c (95% CI: 41-87; n=18)

*at 180mg once daily regimen with a 7-day lead in at 90mg once daily
a=Independent Review Committee;
b= in patients with any brain metastases at baseline;
c=patients with measurable brain metastases at baseline

ALK+ = anaplastic lymphoma kinase positive; CI = confidence interval; CNS = central nervous system; NR = not reached; NSCLC = non small cell lung cancer; ORR = objective response rate; OS = overall survival; PFS = progression free survival

References:
1. Alunbrig HK prescribing information (HK-Nov18-US-Oct17)
2. Huber RM et al., J Thorac Oncol. 2020;15(3):404-415


Further information is available in MIMS section 9d and MIMS online.

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 03 Feb 2020
Treatment with semaglutide leads to clinically significant decreases in haemoglobin A1C (HbA1c) and body weight in patients with type 2 diabetes (T2D) across the SUSTAIN 1–7 trials, regardless of race and ethnicity, results of a posthoc analysis have shown.
2 days ago
Use of metformin is effective in preventing hyperglycaemia in nondiabetic cancer patients exposed to high-dose prednisone-based chemotherapy, results of a randomized study have shown.
Pearl Toh, 06 Feb 2020
The type I interferon receptor subunit 1 mAb* anifrolumab significantly improves response in patients with systemic lupus erythematosus (SLE) in the second phase III randomized trial of the drug, TULIP-2** — in contrast to the first trial.
27 May 2020
The perception that proton pump inhibitors (PPIs) cause multiple serious adverse effects (AEs) is supported by many internists, who then recommend treatment cessation even in patients at high risk for upper gastrointestinal bleeding (UGIB), reveals a study.